CompletedPhase 2NCT02259725
Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
Studying Zollinger-Ellison syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Southern California
- Principal Investigator
- Syma Iqbal, MDUniversity of Southern California
- Intervention
- regorafenib(drug)
- Enrollment
- 3 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2016 – 2020
Study locations (5)
- Mayo Clinic in Arizona, Scottsdale, Arizona, United States
- USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
- Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
- USC Norris Oncology Hematology-Newport Beach, Newport Beach, California, United States
- Seattle Cancer Care Alliance, Seattle, Washington, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02259725 on ClinicalTrials.govOther trials for Zollinger-Ellison syndrome
Additional recruiting or active studies for the same condition.